Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Merck : Why Merck Is Playing Catch-Up in the Coronavirus -2-

10/23/2020 | 12:49pm EST

Last month, Merck began an early-stage trial of its other experimental Covid-19 vaccine. This one contains a weakened version of the virus that causes measles, and aims to deliver coronavirus's spike protein to the immune system, helping trigger an immune response.

Merck's approach wins the backing of some acclaimed scientists who note the company is using proven technology that can be scaled up readily for manufacture.

"They've been there, they've done it," says William Haseltine, a pioneering scientist of cancer and HIV drugs, and human genome projects.

Write to Gregory Zuckerman at gregory.zuckerman@wsj.com and GJared S. Hopkins at jared.hopkins@wsj.com

(END) Dow Jones Newswires

10-23-20 1248ET

All news about MERCK & CO., INC.
11/27OF MOLECULES & MEDICINE : Dr Maurice Hilleman ("The Father Of Modern Vaccines")
AQ
11/24MERCK : Submits Applications for Licensure of V114, the Company's Investigationa..
AQ
11/24CORCEPT THERAPEUTICS INCORPORATED : Appoints Gillian M. Cannon, PhD, to Board of..
AQ
11/24MERCK : to Acquire OncoImmune
AQ
11/23GLOBAL MARKETS LIVE: Boeing’s 737 Max to resume flights in Europe, Merck’s la..
11/23MERCK : Correction to Merck to Buy OncoImmune Article
DJ
11/23Merck to Buy OncoImmune for $425 Million Amid Race for Covid-19 Treatments --..
DJ
11/23MERCK : Applies in U.S., Europe to License V114 Pneumococcal Conjugate Vaccine
DJ
11/23Merck to Buy OncoImmune Amid Covid-19 Vaccine Development
DJ
11/23MERCK : Submits Applications for Licensure of V114, the Company's Investigationa..
BU
More news
Financials (USD)
Sales 2020 48 147 M - -
Net income 2020 11 964 M - -
Net Debt 2020 14 612 M - -
P/E ratio 2020 17,0x
Yield 2020 3,05%
Capitalization 202 B 202 B -
EV / Sales 2020 4,50x
EV / Sales 2021 4,16x
Nbr of Employees 71 000
Free-Float 70,7%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Average target price 96,05 $
Last Close Price 79,86 $
Spread / Highest target 34,0%
Spread / Average Target 20,3%
Spread / Lowest Target 6,44%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
Thomas Henry Glocer Independent Director
Leslie A. Brun Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.-12.19%202 049
DAIICHI SANKYO COMPANY, LIMITED56.60%72 682
JIANGSU HENGRUI MEDICINE CO., LTD.17.92%69 850
YUNNAN BAIYAO GROUP CO.,LTD7.23%18 673
ORION OYJ-3.10%6 712
SWEDISH ORPHAN BIOVITRUM AB1.42%5 440